| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,026 | 0,067 | 16.12. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.12. | IN BRIEF: GENinCode inks commercialisation deal with Thermo Fisher | 4 | Alliance News | ||
| 04.12. | AIM WINNERS & LOSERS: GENinCode strikes deal; Metals One falls | 6 | Alliance News | ||
| 04.12. | GENinCode PLC - Collaboration with Thermo Fisher | 6 | RNS | ||
| 03.12. | AIM Market Roundup: Genincode, Proteome Sciences, Caspian Sunrise | 1 | The Armchair Trader | ||
| 03.12. | GENinCode shares soar on New York heart health test approval | 1 | Alliance News | ||
| 03.12. | AIM WINNERS & LOSERS: GENinCode jumps; Physiomics CEO to step down | 1 | Alliance News | ||
| GENINCODE Aktie jetzt für 0€ handeln | |||||
| 03.12. | GENinCode PLC - Approval of CARDIO inCode-score in New York state | 2 | RNS | ||
| 12.11. | GENinCode US inc: New Study From GENinCode Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction | 290 | ACCESS Newswire | NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association ("AHA") Conference 2025, GENinCode the predictive genetics company focused on the prevention of cardiovascular... ► Artikel lesen | |
| 28.10. | GENinCode US inc: Publication of Landmark Study in JACC: Advances | 201 | ACCESS Newswire | CARDIO inCode-Score Genetic Risk Influences Cholesterol Risk and Prediction of Coronary Heart Disease IRVINE, CA / ACCESS Newswire / October 28, 2025 / GENinCode, the predictive genetics company focused... ► Artikel lesen | |
| 27.10. | GENinCode PLC - Publication of Landmark Study in JACC: Advances | - | RNS | ||
| 30.09. | EARNINGS: GENinCode sees annual revenue growth slower than expected | 1 | Alliance News | ||
| 30.09. | GENinCode lowers outlook, shares slide | 1 | Sharecast | ||
| 30.09. | GENinCode PLC - Half-year Report | - | RNS | ||
| 25.09. | GENinCode PLC - NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch | - | RNS | ||
| 17.09. | GENinCode has no explanation for share movement, reaffirms position | 1 | Alliance News | ||
| 17.09. | GENinCode PLC - Stmnt re Share Price Movement | - | RNS | ||
| 16.09. | AIM Market Roundup: Genincode, Silver Bullet, Focusrite | 3 | The Armchair Trader | ||
| 05.09. | GENinCode PLC - Notice of Results | - | RNS | ||
| 26.08. | GENinCode H1 revenues grow, losses unchanged YOY | 1 | Sharecast | ||
| 26.08. | GENinCode PLC - Trading update | - | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 44,210 | -0,38 % | Aktien Frankfurt Ausblick: Dax dürfte vor US-Zinsentscheidung leicht schwächeln | FRANKFURT (dpa-AFX) - Vor der US-Leitzinsentscheidung an diesem Abend dürften die Anleger am deutschen Aktienmarkt einen Gang herunterschalten. Der Dax wurde rund eine Stunde vor Beginn des Börsenhandels... ► Artikel lesen | |
| FRESENIUS | 47,430 | -2,21 % | AKTIEN IM FOKUS: Medizintechnikwerte von Exane bewegt - 'Zweigeteiltes 2026' | FRANKFURT (dpa-AFX) - Die Aktien von Siemens Healthineers und Sartorius haben am Mittwoch nach einer Studie von Exane BNP Paribas zum europäischen Medizintechniksektor unterschiedliche Richtungen eingeschlagen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,180 | +0,53 % | FMC, Hugo Boss, Kontron, PVA TePla, Suss MicroTec, TeamViewer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 36,440 | +1,33 % | BrightSpring upgraded at KeyBanc on specialty pharmacy and EBITDA prospects | ||
| GENEDX | 141,66 | -5,95 % | GeneDx and Guardant Health named as BTIG's top picks for 2026 | ||
| CARL ZEISS MEDITEC | 39,940 | -0,45 % | Carl Zeiss Meditec: Auftragsboom, aber Gewinn-Delle - Comeback-Story im TecDAX? | Carl Zeiss Meditec AG liefert zum Geschäftsjahr 2024/25 ein gemischtes, aber durchaus spannendes Bild ab: Umsatz +7,8 % auf 2.228 Mio. Euro, der Auftragseingang legt sogar um +18,2 % zu - doch Gewinn... ► Artikel lesen | |
| HEARTBEAM | 3,435 | 0,00 % | Heartbeam stock is a buy, this analyst says | ||
| ALIGNMENT HEALTHCARE | 20,030 | -0,40 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| GERRESHEIMER | 27,060 | -3,77 % | Evonik, Gerresheimer, Hugo Boss, K+S, RWE, Siltronic - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BETA BIONICS | 29,630 | -0,30 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| CLEARPOINT NEURO | 13,820 | +11,63 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Completes Acquisition of IRRAS | Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire... ► Artikel lesen | |
| LUMEXA IMAGING | 17,830 | -3,62 % | Lumexa Imaging Announces Pricing of Initial Public Offering | RALEIGH, N.C., Dec. 10, 2025 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") announced today the pricing of its initial public offering of 25,000... ► Artikel lesen | |
| PROGYNY | 26,020 | -1,29 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| VENUS CONCEPT | 2,260 | 0,00 % | Venus Concept Inc.: Venus Concept Announces Third Quarter 2025 Financial Results | TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 35,650 | -0,03 % | UBS stuft Procept BioRobotics mit "Buy" ein - Wachstum bei Systemauslastung als Treiber |